Beirne Wealth Consulting Services LLC cut its position in DURECT Co. (NASDAQ:DRRX – Free Report) by 13.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 325,875 shares of the specialty pharmaceutical company’s stock after selling 50,501 shares during the quarter. Beirne Wealth Consulting Services LLC owned about 1.05% of DURECT worth $244,000 as of its most recent SEC filing.
Separately, Geode Capital Management LLC grew its position in shares of DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after acquiring an additional 14,658 shares during the period. Institutional investors own 28.03% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the stock. StockNews.com initiated coverage on shares of DURECT in a report on Saturday. They issued a “sell” rating on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.
DURECT Stock Performance
NASDAQ DRRX opened at $0.77 on Wednesday. DURECT Co. has a 52-week low of $0.70 and a 52-week high of $1.88. The stock has a market cap of $23.87 million, a PE ratio of -1.26 and a beta of 0.91. The firm has a 50-day moving average of $0.83 and a 200-day moving average of $1.12.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Read More
- Five stocks we like better than DURECT
- What is a Dividend King?
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- What is the Hang Seng index?
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.
